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ABSTRACT 
Introduction. Ipilimumab is a monoclonal antibody registered for the treatment of patients with unresectable or 
metastatic melanoma. Studies have shown prolongation of overall survival in patients treated with ipilimumab. 
Adverse events related to excessive stimulation of the immune system may occur during treatment. The aim of this 
paper was to analyse the results of treatment with the use of ipilimumab, which were achieved in one institution 
in the frame of a therapeutic program established in Poland. 
Materials and methods. Forty-seven patients (27 men, 20 women) were treated from April 2014 to February 
2015 with ipilimumab in a dose of 3 mg/kg of body weight after failure of one previous systemic line of treatment. 
Median age at the beginning of the treatment was 54 years (range 18–73). Nineteen patients (40%) had BRAF 
mutation. Thirty patients received chemotherapy as first-line treatment prior to ipilimumab, 14 patients were given 
vemurafenib, and three patients were treated in clinical trials. Performance status 0 or 1 was found in 15 patients 
and 32 patients, respectively. Five patients (10.6%) had asymptomatic brain metastases. Twenty-four (51%) patients 
had metastatic disease with three or less organs involved, whereas 23 (49%) patients had metastases in more 
than three organs. Lactate dehydrogenase (LDH) activity and neutrophil count was elevated at the beginning of 
treatment in 40% and 30% of patients, respectively. 
Results. Thirty-five patients (74%) completed four doses of treatment. Four patients (8.5%) had partial response to 
the treatment, 12 patients (25.5%) had stable disease (SD) for three or more months, and 31 (66%) had progres-
sive disease. Sixteen patients (34%) had clinical benefit from the treatment (PR + SD). Median progression-free 
survival (PFS) time was two months. Median overall survival (OS) time was 7.5 months. Increased LDH activity 
at the beginning of treatment and elevated neutrophil count significantly influenced overall survival of patients 
(p = 0.005 and p = 0.01, respectively). After progression on ipilimumab 25 patients (53%) received further lines 
of systemic treatment. 
Conclusions. This analysis confirms the efficacy of ipilimumab in some patients with advanced melanoma in 
second-line systemic therapy. A limited proportion of patients obtain long lasting control of the disease after use 
of ipilimumab with good tolerance to the treatment. There is a need to determine predictive factors of response 
to treatment for better selection of patients.
Key words: melanoma, ipilimumab, survival, toxicity
Oncol Clin Pract 2015; 11, 5: 256–262
Introduction 
Melanoma is an aggressive skin cancer, characterised 
by a high risk of metastatic spread. The incidence of 
melanoma is increasing and also raises the percentage 
of patients diagnosed with metastatic disease, whose 
prognosis remains poor. Survival outcomes for pa-
tients with advanced melanoma have historically been 
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poor, with the five-year survival rate for patients with 
stage IV disease not higher than 5–10%, and median 
overall survival (OS) of 6–9 months [1, 2]. In the year 
2010 in Poland the number of new patients diagnosed 
with melanoma was 1200 men and 1350 women, and 
1200 died because of distant melanoma spread (more 
than 600 men and 570 women) [3]. Until recently, the 
only option for the palliative treatment of patients with 
a diagnosis of metastatic melanoma was chemotherapy 
based on dacarbazine, the efficacy of which was low 
(no impact on overall survival). In recent years the 
results of a series of clinical trials for new molecules 
have been published, some of which have already been 
registered and are used in practice. This has translated 
into a survival advantage in this group of patients with 
poor-prognosis [4, 5].
One of the new drugs is ipilimumab, which is 
a human monoclonal antibody blocking the antigen 
CTLA-4 (cytotoxic T-lymphocyte-associated antigen 4) 
on the surface of T lymphocytes. The blockade of 
CTLA-4 increases the activity of lymphocytes and re-
moves the mechanisms of immune tolerance; it causes en-
hanced activation of cytotoxic lymphocytes and decreases 
the control by the suppressor cells [6]. In the year 2010 the 
results of a multicentre randomised trial were published 
on the efficacy of ipilimumab in patients diagnosed with 
metastatic melanoma, who had failed prior treatment. 
It showed improved OS, for the first time for a systemic 
therapy for melanoma. Median OS in the group receiving 
ipilimumab treatment (at a dose of 3 mg/kg body weight) 
was 10 months, compared to 6.4 months in the control 
group (patients receiving the vaccine gp100); this differ-
ence was statistically significant. Among patients treated 
with ipilimumab the objective response rate was rather 
low (10.9%), but the two-year survival in patients receiv-
ing immunotherapy reached about 20%. In the group of 
patients treated with ipilimumab 10–15% had side effects 
of treatment in grade 3 or 4 according to the CTC (Com-
mon Toxicity Criteria) [7]. The efficacy of the drug was 
confirmed in the following clinical study. This time the 
trial was conducted in previously untreated patients. Me-
dian OS in the group treated with the combination of 
ipilimumab and dacarbazine was 11.2 months, compared 
to 9.1 months in patients receiving dacarbazine alone, 
one-year survival rate was 47.3% vs. 36.3%, and two-year 
survival was 28.5% to 17.9% (HR 0.72, p < 0.001). In 
this study, ipilimumab was administered at a dose of 
10 mg/kg body weight [8].
The results of these studies were the basis for the 
registration of ipilimumab in the European Union for 
the treatment of patients diagnosed with skin and mu-
cosal melanoma in local unresectable stage or metastatic 
disease. In the year 2011 the drug was initially registered 
in the second-line of treatment, in 2013 this registration 
was extended also to the first line of treatment.
In Poland, the drug has been available as part of the 
drug program of the National Health Fund (NFZ) since 
March 2014 for the second-line treatment of patients 
diagnosed with melanoma of the skin or mucous mem-
branes in stage III (unresectable) or IV. The program 
has been implemented in nineteen oncology centres 
in the country, and more than 200 patients have been 
treated so far.
The aim of the study was to analyse the results of 
efficacy and safety of ipilimumab in patients treated 
in the Department of Soft Tissue, Bone Sarcoma, and 
Melanoma (KNTMKiCz) of the Memorial Cancer 
Centre and Institute of Oncology in Warsaw as part of 
the therapeutic program of the National Health Fund.
Materials and methods
To this retrospective analysis were included 47 pa-
tients (20 female, 27 male). All patients were treated 
with palliative ipilimumab in KNTMKiCz because of 
melanoma of the skin or mucous membranes in stage 
III (inoperative) or IV (distant spread of the disease) 
in the period from April 2014 to February 2015. All 
patients received ipilimumab in the second line of treat-
ment. The median age at treatment was 54 years (range 
18–73 years). Detailed characteristics of patients are 
shown in Table 1.
Ipilimumab was administered in a 1.5-hour infusion 
at a dose of 3 mg/kg of body weight in four cycles every 
21 days. Response to treatment was assessed according 
to the criteria of the immune response using — among 
others — with computed tomography 12 weeks after 
the start of treatment or after administration of the last 
dose of the entire treatment.
Statistical analysis was performed using the software 
package Statistica Version 7 (StatSoft). For the survival 
curves, the median survival time was estimated by the 
Kaplan-Meier method. Overall survival was calculated 
from the date of initiation of treatment with ipilimumab 
to the date of last follow-up or death. Time of progres-
sion-free survival (PFS) was calculated from the date 
of initiation of treatment with ipilimumab to the date 
of last follow-up or radiologically proven progression 
of the disease. The median follow-up time was seven 
months. Side effects of the treatment were evaluated 
according to the CTC criteria (version 4).
Results 
Efficacy
Thirty-five patients (74%) received the full four 
treatment doses. Among the 12 patients who did not 
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complete the planned treatment, in nine the reason 
for discontinuation was progression of cancer, in three 
patients it was the toxicity of treatment. None of the 
patients achieved complete response to therapy (CR); 
four patients (8.5%) had a partial response to treatment 
(PR) (Figure 1). Disease stabilisation (SD) lasting three 
months or longer was found in 12 (25.5%) of the treated, 
and 31 (66%) patients had progressive disease (PD). In 
sixteen (34%) patients a clinical benefit of the treatment 
(PR + SD) could be observed. The phenomenon of 
pseudo progression of the cancer did not occur in the 
observed group.
The median PFS was two months (Figure 2). The 
median PFS was six months in the group of patients 
who achieved control of the disease after ipilimumab 
treatment. Performance status, the presence of meta-
static lesions in the CNS, the spread of the disease or 
baseline albumin, LDH level, and neutrophil count had 
no statistically significant impact on the PFS. Median 
OS was 7.5 months (Figure 3). In the group of patients 
who achieved control of the disease, median OS was not 
reached. An important difference with respect to OS 
was, according to the initial activity of LDH (p = 0.005) 
(Figure 4), elevated baseline count of neutrophils had 
also a negative impact on survival (p = 0.01) (Figure 5). 
No statistically significant impact on overall survival 
could be seen in the groups of patients with worst gen-
eral condition, with the presence of metastatic lesions in 
the CNS, metastatic spread to more than three organs, 
or decreased baseline albumin level. At the time of the 
analysis, there were 26 patients who had died. After 
disease progression on ipilimumab 25 patients (53%) 
received further systemic therapy (3 — chemotherapy, 
21 — pembrolizumab, 1 — dabrafenib).
Table 1. Patient characteristics 
Patient characteristics (n = 47) Number %
Sex
     Female
     Men
20
27
42
58
ECOG performance status
     0
     1
15
32
32
68
Localisation of the primary lesion
      Skin
     Unknown
     Mucous membranes
38
6
3
80
12.7
6.3
First-line treatment
     Chemotherapy
     Vemurafenib
     Clinical trial
30
14
3
64
30
6
BRAF mutation
     Yes
     No
19
28
40
60
Spread of the disease:
     Spread to ≤ 3 organs 
     Spread to > 3 organs
24
23
51
49
Metastases in the central nervous system
     Yes
     No
5
42
10.6
89.3
Baseline albumin level
     Normal
     Below normal
      
28
19
60
40
Baseline lactate dehydrogenase (LDH) level
     Normal
     Below normal
28
19
60
40
Baseline neutrophil count  
     Normal
     Below normal
33
14
70
30
Figure 1. Partial regression of the disease after four doses of treatment
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Figure 2. Progression-free survival (PFS)
Figure 3. Overall survival (OS)
Figure 4. Overall survival (OS) according to baseline LDH level
Figure 5. Overall survival (OS) according to baseline neutrophil count
Adverse events
The treatment was rather well tolerated. Eighteen 
patients (38%) had side effects of treatment. Only three 
patients discontinued the therapy due to toxi city. There 
were no deaths due to toxicity of treatment. Seven pa-
tients had a thyroid dysfunction in stage 1 of the CTC 
(asymptomatic variations in hormone levels). Four pa-
tients experienced skin rash degree CTC 1 or 2, which 
decreased without additional treatment (Figure 6). 
One patient had transaminase elevations in stage 1 
of the CTC. Six patients (12.7%) had adverse reactions 
in a higher degree requiring the use of high doses of 
corticosteroids in accordance with the recommended 
algorithms [9]. Five patients had grade 3 diarrhoea by 
CTC (more than seven bowel movements daily), and 
one patient experienced inflammation of the pituitary 
Grade 3. None of these patients required use of immu-
nosuppressive therapy recommended in the algorithms 
other than corticosteroids (e.g. Infliximab used for pa-
tients who developed severe autoimmune inflammatory 
bowel disease).
Discussion
Ipilimumab is a drug that has been thoroughly in-
vestigated in clinical trials. Especially interesting — in 
the context of the current work — are the analyses on 
the efficacy and safety of treatment derived from the 
so-called expanded access programs, to which patients 
were included before the official registration of the 
drug. The results of these studies are usually slightly 
different from comming from clinical studies, where the 
inclusion criteria are quite rigorous and many patients 
commonly seen in everyday clinical practice are less 
represented (e.g. after failure of a number of prior lines 
of therapy). It is worth mentioning the results of the 
Polish expanded access program, published in 2013. Fifty 
patients from five cancer centres were treated. The 
results are reasonably consistent with those obtained in 
the present analysis: 70% of patients received the full 
four doses of treatment. Although the median PFS was 
longer (three months), the median OS was similar (eight 
months). A factor significantly affecting the prognosis of 
patients was performance status at the treatment start 
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it was much longer in those who achieved response to 
treatment (42.3 months in the Czech Republic; in the 
following analysis the median OS in this group was not 
reached) [13].
There are currently attempts to assess predictive 
factors of response to ipilimumab. Response to immu-
notherapy has a different dynamic than that observed 
when using targeted therapy or classical systemic 
therapy. The expected positive response to ipilimumab 
is stabilisation of the disease or slow decrease in tumour 
lesions rather than rapid regression of the tumour. Pa-
tients with rapidly extending malignancies and/or high 
tumour burden in most cases do not benefit from immu-
notherapy. The delayed response to treatment (weeks 
or even months after its start) justifies carrying out the 
first radiological evaluation of efficacy after the admin-
istration of all (four) drug doses [14]. Therefore, there 
are relatively high percentages of patients failing to end 
the full course of treatment due to disease progression. 
Less benefit from treatment with ipilimumab in patients 
with high levels of disease was shown, among other re-
sults, in a randomised study of patients diagnosed with 
metastatic melanoma to the CNS. The study enrolled 
asymptomatic patients who did not require the use of 
corticosteroids and those whose symptoms of the disease 
required use of stable doses of corticosteroids. Median 
PFS and OS in asymptomatic patients were twice as long 
as in patients in need of treatment against oedema [15]. 
One of the indicators of high activity of cancer is 
increased LDH level. LDH level exceeding the upper 
normal limit has for years been known as a poor prognos-
tic factor in melanoma patients [16, 17]. Poor prognosis 
for melanoma patients diagnosed with elevated LDH 
levels also applies to those treated with ipilimumab. In 
a large analysis of predictive factors of patients treated 
with ipilimumab conducted in the UK and the Nether-
lands, elevated LDH levels was the strongest negative 
factor among those examined. The study conclusion was 
that patients with a baseline LDH activity exceeding the 
upper normal limit by a factor of two are unlikely to 
benefit from treatment with ipilimumabem [18]. Also, 
in our analysed group of patients who at baseline had 
elevated LDH levels, significantly shorter OS was seen 
compared with those in whom the level was within nor-
mal limits. Another factor with a negative predictor of 
outcome in the analysed group was elevated baseline 
neutrophil count. Both indicators (baseline LDH level 
and neutrophil count) were also singled out as strong 
and independent prognostic factors among patients 
treated with ipilimumab in the nomogram proposed 
this year aiming to help in the inclusion of patients for 
treatment [19].
During ipilimumab treatment rather unique toxic-
ity can occur, previously not commonly found in the 
systemic treatment of cancer. This toxicity is associated 
Figure 6. Skin rash grade 2 CTC in a patient after two doses 
of treatment
 
[10]. Further data are presented from Spanish centres, 
where the results come from 153 patients enrolled in 
the program, of which 61% received the full four doses 
of treatment. Complete response was observed in 1.3% 
of patients, a partial response was observed in 9.6% of 
patients, and stable disease in 14.5%. Median OS was 
6.5 months. Negative prognostic factors for survival 
proved to be an increased lymphocyte count and in-
creased LDH activity [11]. In the UK 193 patients were 
included in the expanded access program, including 
20% with a diagnosis of metastatic lesions to the CNS. 
Only 53% of patients received the full four doses of the 
drug; among those who did not complete the treatment 
the main cause was progression of the disease. The 
median PFS was 2.8 months, and median OS reached 
6.1 months. The objective response rate to treatment 
was 14% [12]. A significant number of patients treated 
with ipilimumab (196) were included in the recently 
published analysis from Czech centres. A full course of 
treatment was received by 66.8% of patients. Median 
OS was — similarly to our group — 7.5 months, and 
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with overstimulation of the immune system. Algorithms 
have been developed in the case of these adverse ef-
fects, the use of which strongly reduces the risk of toxic 
accumulation; in the treatment of ipilimumab adverse 
events are used immunosuppressive drugs (primarily 
corticosteroids) [9, 20]. In the registration study, side 
effects of treatment were observed in 60% of patients 
treated with ipilimumab, with toxicity of grade 3 or 4 in 
10–15% of patients, wherein 14 patients (2.1%) died 
due to treatment toxicity [7]. In the past, drug toxicity 
among patients treated in routine clinical practice seems 
to be slightly higher. This may be due to the often less 
stringent control and less frequent visits to the treating 
centre than among patients participating in clinical 
trials. With the already quoted analysis of data from 
the expanded access program in the UK, toxicity of 
treatment was observed in 70% of patients, and 30% 
of patients had adverse reactions Grade 3 or higher 
(usually diarrhoea). In 10% of patients of this group, the 
treatment was discontinued because of toxicity [12]. In 
the analysed group, the percentage of adverse events was 
not high — side effects of treatment were observed in 
38% of patients, and grade 3 toxicity occurred in 12.7% 
of patients, with no treatment-related deaths. Due to 
the specific profile of adverse drug reactions, the treat-
ment of which requires experience and multidisciplinary 
facilities (e.g. endoscopy), ipilimumab treatment should 
be carried out in major cancer centres with relevant 
experience. Patients should be thoroughly informed 
about the possible side effects of the drug and should be 
instructed to react quickly and contact the care provider 
centre if they occur [21].
Conclusions
The presented results confirm the efficacy and 
safety of ipilimumab treatment in patients diagnosed 
with advanced melanoma, after failure of prior lines of 
therapy. In the analysed group prognosis is similar to 
that presented in previous publications. A limitation 
of the above analysis is certainly the relatively short 
observation period, which does not allow a full assess-
ment of the duration of response and overall survival. 
It is also recommended to repeat the analyses after 
obtaining data from a larger number of patients from 
other centres in Poland.
Ipilimumab is not a drug that leads to a high percent-
age of objective response to treatment, but some of the 
treated patients manage to achieve long-term control 
of the with good tolerability. It is advisable to carefully 
select patients for treatment, due to the specific kinet-
ics of response. The slow time of onset of the response 
(as opposed to the rapid response seen e.g. when using 
BRAF inhibitors) restricts the use of ipilimumab in 
patients with dynamic course of the disease accompanied 
by a rapid deterioration of general condition. The rule 
of eligibility is often difficult in such clinical situations 
as disseminated malignancy and the need to propose 
patients access to the latest therapies. It should also be 
considered whether the drug’s availability in Poland only 
in the second-line treatment does not limit its therapeu-
tic possibilities. Often patients after failure of first-line 
systemic therapy already have majorly advanced dis-
ease with progressing rapidly deterioration of general 
condition, thus being poor candidates for ipilimumab 
use. Thiese limitations do not change the fact that ipili-
mumab is an effective drug that gives hope for long-term 
survival to very poor-prognosis patients. Moreover, the 
results of this work can be the starting point for chang-
ing current strategy for immunotherapy of melanoma 
in the case of detection of inoperable metastases in the 
treatment of anti-PD-1 (nivolumab or pembrolizumab), 
which are more effective, with a median overall survival 
of up to two years and better tolerance [22, 23], or imple-
mentation of a combined therapy with anti-CTLA-4 and 
anti-PD-1 (with a greater toxicity and cost of the com-
bination drug) [24].
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